This educational activity is specifically designed for oncologists, hematologists, and other healthcare professionals, including nurses and pharmacists, interested and/or involved in the care of patients with cancer.
Objectives After successful completion of this course, participants should be able to:
- Identify recent advances in therapy for breast cancer, especially for metastatic ERBB2 (formerly HER2) positive tumors, and optimize chemotherapeutic regimens
- Identify emerging trends in adjuvant therapy for colorectal cancer (CRC), and optimize management of upper GI tract adenocarcinoma
- Describe recent advances in hematologic malignancies, especially frontline therapy for newly diagnosed myeloma, as well as genetic and molecular factors in planning therapy for acute leukemia
- Optimize sequencing and combinations of current and emerging therapies in renal cell carcinoma (RCC) and castrate-resistant prostate cancer
- Identify emerging adjuvant and maintenance therapies for non-small-cell lung cancer (NSCLC) and discuss options after postmaintenance relapse
- Evaluate therapeutic advances and clinical updates in orphan cancers such as T-cell lymphoma, melanoma, small-cell lung, thyroid, and biliary tract cancers
